JP2019531346A - 甲状腺関連副作用を低下させる方法 - Google Patents

甲状腺関連副作用を低下させる方法 Download PDF

Info

Publication number
JP2019531346A
JP2019531346A JP2019536463A JP2019536463A JP2019531346A JP 2019531346 A JP2019531346 A JP 2019531346A JP 2019536463 A JP2019536463 A JP 2019536463A JP 2019536463 A JP2019536463 A JP 2019536463A JP 2019531346 A JP2019531346 A JP 2019531346A
Authority
JP
Japan
Prior art keywords
optionally substituted
days
group
alkyl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019536463A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019531346A5 (enExample
Inventor
ブライアン・リアン
ヒロコ・マサムネ
マーク・エリオン
ブルース・イトウ
Original Assignee
バイキング・セラピューティクス・インコーポレイテッド
メタベイシス・セラピューティクス・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイキング・セラピューティクス・インコーポレイテッド, メタベイシス・セラピューティクス・インコーポレイテッド filed Critical バイキング・セラピューティクス・インコーポレイテッド
Publication of JP2019531346A publication Critical patent/JP2019531346A/ja
Publication of JP2019531346A5 publication Critical patent/JP2019531346A5/ja
Priority to JP2022148311A priority Critical patent/JP7656574B2/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Fats And Perfumes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2019536463A 2016-09-16 2017-09-13 甲状腺関連副作用を低下させる方法 Pending JP2019531346A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022148311A JP7656574B2 (ja) 2016-09-16 2022-09-16 甲状腺関連副作用を低下させる方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662396015P 2016-09-16 2016-09-16
US201662396025P 2016-09-16 2016-09-16
US62/396,025 2016-09-16
US62/396,015 2016-09-16
PCT/US2017/051410 WO2018053036A1 (en) 2016-09-16 2017-09-13 Method of reducing thyroid-associated side effects

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022148311A Division JP7656574B2 (ja) 2016-09-16 2022-09-16 甲状腺関連副作用を低下させる方法

Publications (2)

Publication Number Publication Date
JP2019531346A true JP2019531346A (ja) 2019-10-31
JP2019531346A5 JP2019531346A5 (enExample) 2020-10-22

Family

ID=61619247

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019536463A Pending JP2019531346A (ja) 2016-09-16 2017-09-13 甲状腺関連副作用を低下させる方法
JP2022148311A Active JP7656574B2 (ja) 2016-09-16 2022-09-16 甲状腺関連副作用を低下させる方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022148311A Active JP7656574B2 (ja) 2016-09-16 2022-09-16 甲状腺関連副作用を低下させる方法

Country Status (9)

Country Link
US (1) US20190255080A1 (enExample)
EP (1) EP3512523A4 (enExample)
JP (2) JP2019531346A (enExample)
KR (2) KR20240074912A (enExample)
CN (1) CN109922812A (enExample)
AU (1) AU2017327383B2 (enExample)
CA (1) CA3037146A1 (enExample)
MX (2) MX2019003032A (enExample)
WO (1) WO2018053036A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022544943A (ja) * 2020-02-24 2022-10-24 へパジーン セラピューティクス （エイチケイ） リミテッド 複素環式ＴＨＲ－β受容体アゴニスト化合物ならびにその調製方法および使用
US12378268B2 (en) 2019-08-19 2025-08-05 Hepagene Therapeutics (HK) Limited Heterocyclic THR-β receptor agonist compound and preparation method and use therefor

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090232879A1 (en) 2005-05-26 2009-09-17 Metabasis Therapeutics, Inc. Thyromimetics for the Treatment of Fatty Liver Diseases
JP2020500199A (ja) 2016-11-21 2020-01-09 バイキング・セラピューティクス・インコーポレイテッド グリコーゲン蓄積症の治療方法
AU2018280118B2 (en) 2017-06-05 2021-07-15 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis
EA202091979A1 (ru) 2018-03-22 2021-06-22 Вайкинг Терапьютикс, Инк. Кристаллические формы и способы получения кристаллических форм соединения
US12102646B2 (en) 2018-12-05 2024-10-01 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis and inflammation
JP2021518854A (ja) * 2019-05-08 2021-08-05 ノバルティス アーゲー Ｔ１ｄｍ及び膵島炎の治療に使用するための抗ｃｄ４０抗体
RU2728261C2 (ru) * 2019-05-22 2020-07-28 Ирина Алексеевна Курникова Способ дифференциальной диагностики йоддефицитного и йодиндуцированного нарушения функции щитовидной железы у лиц, проживающих в регионах с йодным дефицитом
CN112457346B (zh) * 2019-08-19 2022-09-06 和博医药有限公司 一种并环THRβ受体激动剂化合物及其制备方法和用途
US11752161B2 (en) 2020-03-27 2023-09-12 Gannex Pharma Co., Ltd. Pharmaceutical compositions, method of making and method of using thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007512359A (ja) * 2003-11-19 2007-05-17 メタバシス・セラピューティクス・インコーポレイテッド 新規なリン含有甲状腺ホルモン様物質
WO2011038207A1 (en) * 2009-09-25 2011-03-31 Metabasis Therapeutics, Inc. Phosphorus-containing thyroid hormone receptor agonists and methods of use
JP2012513394A (ja) * 2008-12-22 2012-06-14 オトノミ―，インク． 耳の障害の処置のための耳感覚細胞モジュレータ組成物の制御放出及びその方法
JP2019516783A (ja) * 2016-04-22 2019-06-20 メタベイシス・セラピューティクス・インコーポレイテッド 甲状腺ホルモン受容体アゴニスト及びその使用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
ES2327328T3 (es) * 2002-07-04 2009-10-28 Zealand Pharma A/S Glp-1 y procedimientos para el tratamiento de la diabetes.
US20090232879A1 (en) * 2005-05-26 2009-09-17 Metabasis Therapeutics, Inc. Thyromimetics for the Treatment of Fatty Liver Diseases
WO2009089093A1 (en) * 2008-01-04 2009-07-16 Quatrx Pharmaceuticals Company Thyroid hormone receptor agonists
JP2020500199A (ja) * 2016-11-21 2020-01-09 バイキング・セラピューティクス・インコーポレイテッド グリコーゲン蓄積症の治療方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007512359A (ja) * 2003-11-19 2007-05-17 メタバシス・セラピューティクス・インコーポレイテッド 新規なリン含有甲状腺ホルモン様物質
US7514419B2 (en) * 2003-11-19 2009-04-07 Metabasis Therapeutics, Inc. Phosphorus-containing thyromimetics
JP2012513394A (ja) * 2008-12-22 2012-06-14 オトノミ―，インク． 耳の障害の処置のための耳感覚細胞モジュレータ組成物の制御放出及びその方法
WO2011038207A1 (en) * 2009-09-25 2011-03-31 Metabasis Therapeutics, Inc. Phosphorus-containing thyroid hormone receptor agonists and methods of use
JP2019516783A (ja) * 2016-04-22 2019-06-20 メタベイシス・セラピューティクス・インコーポレイテッド 甲状腺ホルモン受容体アゴニスト及びその使用

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12378268B2 (en) 2019-08-19 2025-08-05 Hepagene Therapeutics (HK) Limited Heterocyclic THR-β receptor agonist compound and preparation method and use therefor
JP2022544943A (ja) * 2020-02-24 2022-10-24 へパジーン セラピューティクス （エイチケイ） リミテッド 複素環式ＴＨＲ－β受容体アゴニスト化合物ならびにその調製方法および使用
JP7670687B2 (ja) 2020-02-24 2025-04-30 へパジーン セラピューティクス （エイチケイ） リミテッド 複素環式ＴＨＲ－β受容体アゴニスト化合物ならびにその調製方法および使用

Also Published As

Publication number Publication date
EP3512523A1 (en) 2019-07-24
JP7656574B2 (ja) 2025-04-03
MX2023000887A (es) 2023-02-22
KR20190060786A (ko) 2019-06-03
KR20240074912A (ko) 2024-05-28
EP3512523A4 (en) 2020-05-06
WO2018053036A1 (en) 2018-03-22
JP2022174261A (ja) 2022-11-22
US20190255080A1 (en) 2019-08-22
AU2017327383A1 (en) 2019-04-11
CN109922812A (zh) 2019-06-21
AU2017327383B2 (en) 2023-06-29
MX2019003032A (es) 2019-09-13
BR112019005039A2 (pt) 2019-06-25
CA3037146A1 (en) 2018-03-22
NZ751857A (en) 2024-05-31

Similar Documents

Publication Publication Date Title
JP7656574B2 (ja) 甲状腺関連副作用を低下させる方法
JP7270688B2 (ja) 貧血治療のための組成物及び方法
KR101909433B1 (ko) 키나제 저해제의 부작용 저감제
JP2020500199A (ja) グリコーゲン蓄積症の治療方法
KR101516677B1 (ko) 지방성 간 질환의 치료용 의약 조성물
JP5680412B2 (ja) レオヌリンの使用およびその組成物
KR100555824B1 (ko) Ｃｏｐｄ의 치료법
KR102512518B1 (ko) 페마피브레이트를 함유하는 의약
CN110831598A (zh) 经鼻给药用医药组合物
BR112019005039B1 (pt) Método de redução dos efeitos colaterais associados à tireoide
US20240325360A1 (en) Therapeutic methods using vadadustat
JP6875747B2 (ja) 生薬成分を含む肺高血圧症の予防又は治療剤
KR20070102694A (ko) 혈당 강하제를 함유하는, 내당능 이상, 경계형 당뇨병,인슐린 저항성 및 고인슐린혈증 개선 또는 치료용 의약조성물
JPH05170653A (ja) 糖尿病治療剤
EA044268B1 (ru) Способ лечения неалкогольной жировой болезни печени
HK1248590B (en) Compositions and methods for treating anemia
WO2005084668A1 (ja) 虚血性循環器疾患の予防及び／又は治療のための薬剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200914

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200914

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210526

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210607

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210906

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220208

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220516

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220916

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220916

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220927

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20221003

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20221014

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20221024

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240502